Welcome to our dedicated page for Currenc Group Ordinary Shares news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group Ordinary Shares stock.
CURE PHARMACEUTICAL HOLDING COR (symbol: CURR), now known as Avenir Wellness Solutions, Inc., is at the forefront of innovative drug delivery and development. The company is dedicated to enhancing drug efficacy, safety, and the overall patient experience through its proprietary drug dosage forms and delivery systems. Avenir boasts an industry-leading full-service CGMP manufacturing facility and is renowned for its advanced oral thin film, Curefilm™, the most sophisticated oral thin film available today.
With a strong presence in the pharmaceutical cannabis sector and partnerships in the U.S., Canada, Israel, and Germany, Avenir is committed to improving how medicines are delivered and experienced worldwide. The company has developed a broad range of products using cutting-edge delivery platforms and collaborates with leading pharmaceutical companies.
Recently, Avenir has experienced significant growth, as evidenced by its financial performance. In the first quarter of 2023, the company reported a 15.1% increase in net revenue year-over-year and a 35.6% sequential increase from Q4 2022, reaching $1.2 million. Gross margins improved by 102 basis points to 78.9%, with further increases expected.
The company's strategic initiatives, including cost reductions and operating leverage, are expected to help narrow the net operating loss from continuing operations, excluding non-cash charges. Avenir's advertising and marketing campaigns, especially for its new product, DNA Complex, have garnered positive attention from prominent media outlets.
On August 9, 2023, the company officially changed its ticker symbol to AVRW and its corporate name to Avenir Wellness Solutions, reflecting its renewed focus on wellness technologies and high-margin products. The rebranding aligns with Avenir's long-term growth strategy to increase revenue through product development, strategic partnerships, and geographic licensing deals.
For more information, visit the company's website at avenirwellness.com.
CURE Pharmaceutical (OTC: CURR) reported a significant Q1 2021 performance, with total revenue soaring over 400% year-on-year to $1.5 million. The company received FDA approval for its Investigational New Drug application for CUREfilm Blue™, targeting erectile dysfunction. Additionally, CURE is advancing clinical development of delivery vehicles for psychedelic compounds. A new line of Nutri-Strips™ vitamins was launched via its Sera Labs subsidiary. CURE also secured a $2.3 million payment from a resolved contract dispute in April 2021.
Sera Labs, part of CURE Pharmaceutical (OTC: CURR), highlighted their participation in Collision 2021, a major tech conference, where CEO Nancy Duitch and actress Nicole Kidman discussed their collaboration and product innovation. The discussion emphasized their upcoming Q2 plant-based product launch and the importance of their proprietary PꝫP complex delivery systems in enhancing product efficacy. Duitch noted that the event generated substantial business momentum for Sera Labs, positioning them to set new standards in wellness and beauty.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced successful results from its Pharmacokinetics (PK)/bioequivalence studies, paving the way for further clinical development aimed at FDA approval. Utilizing its patented CUREfilm technology, the company is developing CUREfilm Blue™, an oral film for sildenafil citrate, enhancing patient experience by eliminating the need to swallow pills. CURE is excited to advance its partnering initiatives for commercialization following these promising results.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that CEO Rob Davidson and Nancy Duitch, CEO of subsidiary Sera Labs, will present at the 2021 Sequire Cannabis Conference on April 20 at 2 p.m. EDT. They will highlight CURE’s patented drug delivery technology and its applications in cannabis and wellness products. The conference showcases over 15 companies, offering insights into investment opportunities in the cannabis sector. Attendees can access a video webcast of the presentation afterward.
Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced that actress Nicole Kidman will headline Collision 2021, North America’s leading tech conference. Kidman and Sera Labs CEO Nancy Duitch are set to discuss innovative delivery system technologies and proprietary methodologies in anti-aging products. The virtual conference from April 20-22, 2021, expects over 40,000 attendees from over 100 countries. Duitch emphasized the significance of this event, showcasing Sera Labs' commitment to leveraging science and technology in beauty and wellness.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a remarkable 229% revenue increase to $2.1 million for the year ended December 31, 2020, driven by its acquisition of The Sera Labs, which contributed $7.7 million in pro forma revenue. Gross profit surged to approximately $1.0 million, up from $0.4 million in 2019. Key operational highlights included FDA approval for CUREfilm® Blue, a new product launch with Sera Labs, and gaining NSF International cGMP certification for its manufacturing facility, positioning CURE as a fully integrated healthcare company.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has secured an extension to its Schedule I DEA license, enabling research into psychedelics like LSD, MDMA, and psilocybin for treating mental health disorders. This license supports integrated research at CURE's FDA-registered facility, bolstering its pharmaceutical pipeline. CURE's existing license facilitates cannabinoid-based drug manufacturing, evidenced by a pharmacokinetic study showing improved bioavailability of its CBD oral film compared to soft gels. The growing interest in psychedelics for mental health treatment positions CURE favorably in an expanding market.
CURE Pharmaceutical Holding Corp. (OTC: CURR) has launched two new clinical development programs aimed at expanding its pharmaceutical pipeline. One program focuses on an antiviral approach utilizing CUREfilm®, the company's patented drug delivery platform, while the other targets anti-seizure therapeutics for both adults and children. The company plans to leverage existing safety and toxicity data to expedite product development. Additionally, CURE is initiating Pharmacokinetics studies for its approved Sildenafil product, CUREfilm® blue, under the 505(b)(2) drug approval pathway, seeking to enhance shareholder value.
CURE Pharmaceutical Holding Corp (OTC: CURR) announced a national advertising campaign for its subsidiary Sera Labs' Nutri-Strips product, Sleep A.S.A.P.™. This initiative targets the 70% of American adults experiencing insufficient sleep, coinciding with National Sleep Awareness Month. The global sleep aids market is projected to grow from $81.2 billion in 2020 to $112.7 billion by 2025. The campaign emphasizes Nutri-Strips’ ease of use and scientifically formulated ingredients designed to promote better sleep.
FAQ
What is the current stock price of Currenc Group Ordinary Shares (CURR)?
What is the market cap of Currenc Group Ordinary Shares (CURR)?
What does Cure Pharmaceutical Holding Corp. do?
What is Curefilm™?
What are the financial highlights for the first quarter of 2023?
What recent changes has Avenir made to its corporate structure?
What is Avenir's mission?
How has Avenir's marketing strategy impacted their business?
What markets does Avenir operate in?
Who are Avenir's notable partners?
What is the significance of the name change to Avenir Wellness Solutions?
Where can I find more information about Avenir's financial performance?
